Flat Pattern Peaks of Tacrolimus Absorption and Associated Pharmacogenomic Variants in Kidney Transplantation Recipients

Suh Min Kim,† Younggyun Lim,‡ Sangil Min,‡ Byung-Joo Min,‡ Myung-Eui Seo,‡ Kye Hwa Lee,§ Ju Han Kim,‡ and Jongwon Ha‡,†

†Department of Surgery, Chung-Ang University College of Medicine, Seoul, Korea
‡Seoul National University Biomedical Informatics (SNUBI), Division of Biomedical Informatics, Seoul National University College of Medicine, Seoul, Korea
§Department of Surgery, Seoul National University College of Medicine, Seoul, Korea
©Department of Information Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
©Transplantation Research Institute, Seoul National University College of Medicine, Seoul, Korea

ABSTRACT

Background: Tacrolimus is the most commonly used immunosuppressive drug in solid organ transplantation. After administering a conventional twice-daily dose of tacrolimus, peak levels were achieved within the first 1.5 to 2 hours. A group of patients showed different early absorption phase of tacrolimus after kidney transplantation.

Methods: Trough (C₀) and 1.5-hour blood levels (C₁.₅) of tacrolimus were measured in 95 kidney transplantation recipients. Patients with a C₁.₅/C₀ < 1.5 and > 1.5 were defined as those having flat pattern peaks and as controls, respectively. Transplantation outcomes were compared between the groups. Whole exome sequencing was performed to investigate the genetic susceptibility to flat pattern peaks.

Results: Twenty-eight patients showed flat pattern peaks. The mean C₁.₅/C₀ values were 1.13 ± 0.22 and 3.78 ± 1.25 in the flat pattern peak and control groups, respectively. In multivariate analysis, flat pattern peak was an independent risk factor for biopsy-proven acute rejection (BPAR) and/or borderline change (P = 0.014). Patients having flat pattern peaks showed significantly lower post-transplant 36-month estimated glomerular filtration rate (P = 0.001). Two single nucleotide variants in ABCB1 genes, rs1922242 and rs2235035, were associated with flat pattern peaks (P = 0.019 and P = 0.027, respectively).

Conclusion: Both of C₁.₅ and C₀ should be measured to distinguish the patients showing unique initial absorption. A C₁.₅/C₀ ratio lower than 1.5 was associated with an increased risk of BPAR and/or borderline change. Single nucleotide variants s in ABCB1 gene might influence the flat pattern peaks of tacrolimus absorption.

Keywords: Tacrolimus; Kidney Transplantation; Pharmacogenomics
INTRODUCTION

Tacrolimus is the most commonly used immunosuppressive drug in solid organ transplantation. Tacrolimus has a narrow therapeutic window and high interpatient variability in terms of bioavailability. Underdosing is associated with an increased risk of rejection, whereas overdosing is associated with drug toxicity. Therefore, therapeutic drug monitoring (TDM) is mandatory. The area under the 24-hour blood concentration-time curve (AUC0-24) can reflect exposure to the drug better than single-time measurement. However, it is difficult to measure the AUC0-24 in clinical practice. Instead, the trough level, which is known to correlate well with the AUC0-24, is used as a marker of drug exposure.

After administering a conventional twice-daily dose of tacrolimus, the initial absorption phase of tacrolimus was observed, and peak levels were achieved within the first 1.5 to 2 hours. However, some patients showed a different pattern of initial absorption. The tacrolimus level in these patients 1 to 4 hours after administration was similar to that observed immediately before the administration. The time-concentration curve would be different from what we expect. If a dose of tacrolimus is administered based on the trough level, the total tacrolimus exposure would be lower than predicted in these patients.

Several extensive studies have examined the pharmacogenomic biomarkers of tacrolimus to refine dose selection. Polymorphisms in genes encoding metabolizing enzymes and drug transporter are associated with the pharmacokinetics of tacrolimus. The cytochrome P450 (CYP) 3A gene, in particular CYP3A5 and CYP3A4, is the most well-known. Additionally, ATP-binding cassette sub-family B member 1 (ABCB 1), P450 oxidoreductase, and solute carrier organic anion have been associated with tacrolimus metabolism.

In this study, we aimed to analyze the association between C1.5/C0 ratio and clinical outcomes, especially the incidence of biopsy-proven acute rejection (BPAR) and/or borderline change, and perform whole exome sequencing to investigate the genetic susceptibility in patients who showed a different pattern of tacrolimus absorption.
tacrolimus (Prograf<sup>®</sup>) was 0.075 mg/kg twice daily; the serum trough level of tacrolimus was adjusted to 8–10 ng/mL until 3 months, 6–8 ng/mL until 1 year, and 4–6 ng/mL thereafter. Mycophenolate was administered at an oral dose of 500 mg twice a day, and the doses were adjusted in patients with hematologic conditions or adverse effects. Methylprednisolone (500 mg) was intravenously administered during surgery and the dose was gradually reduced to 5 mg of oral prednisolone daily.

**Blood concentration of tacrolimus**
Ethylenediaminetetraacetic acid-anticoagulated whole blood samples were collected just before administering the morning dose (C<sub>0</sub>), 1.5 hours after receiving a dose (C<sub>1.5</sub>), and if possible, hourly thereafter. The blood sampling for concentrations of tacrolimus was obtained mostly within a year after transplantation (median 1, range 1–180, mean 10.5 ± 19.3 months). Tacrolimus concentration in whole blood was analyzed by liquid chromatography tandem mass spectrometry using a Waters 2795 Alliance HT system (Waters Ltd., Watford, UK) and a Quattro micro API tandem mass spectrometer (MicroMass, Manchester, UK).<sup>8</sup>

Patients were classified into groups according to C<sub>1.5</sub>/C<sub>0</sub> ratio. Patients with a C<sub>1.5</sub>/C<sub>0</sub> < 1.5 were classified as subjects in the flat pattern peak group, while the remaining patients were included in the control group (Fig. 1). The flat pattern peak was determined based on the C<sub>1.5</sub>/C<sub>0</sub> distribution which showed trimodal pattern. Blood concentration at 3 and 4 hours after a dose was measured to verify the C<sub>1.5</sub> of tacrolimus was the highest.

**Clinical outcomes**
The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease equation. Protocol biopsy was performed at 10 days and 1 year after transplantation. BPAR was included both protocol and for-cause biopsy. Borderline change and rejection were determined according to the criteria proposed at the Banff Conference.<sup>9,10</sup> Delayed graft function was defined as the need for hemodialysis within 1 week after surgery. The primary end-point was the association between C<sub>1.5</sub>/C<sub>0</sub> ratio and clinical outcomes, which were evaluated by incidence of BPAR and/or borderline change and eGFR.

---

**Fig. 1.** A representative time-concentration curve of tacrolimus of each group. (A) Flat pattern peak group showed the similar tacrolimus level observed immediately before the administration and 1 to 4 hours after administration and (B) control group showed the peak levels achieved within the first 1.5 to 2 hours after administration of a conventional twice-daily dose of tacrolimus.
Whole Exome sequencing
Exome sequencing was performed using the Ion AmpliSeq™ Exome panel. The size of amplicons amplified by these oligo primer pairs ranged from 125 to 275 bp. Polymerase chain reaction assays were performed to amplify 100 ng of genomic DNA extracted from the peripheral blood. After amplification, library construction was performed using the Ion AmpliSeq Library Kit Plus (Thermo Fisher Scientific, Waltham, MA, USA) in accordance with the manufacturer's instructions. Libraries were quantified using an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) and then diluted to approximately 10 pM. Subsequently, 33.3 μL of the barcoded libraries were pooled into sets of three barcodes. The combined libraries were sequenced using the Ion Proton platform with PI chip V3 (Thermo Fisher Scientific) following the manufacturer’s instructions.

Variants selection in the CYP3A4, CYP3A5, and ABCB1 genes
Reads were mapped to the human reference genome build (hg19) using a mapping alignment program from Thermo Fisher Scientific (Torrent Suite Software version 4.4) in germ-line and low stringency settings. Single nucleotide variants (SNVs) were called using the Genome Analysis Toolkit 3.8-1 Unified Genotyper. All SNVs were annotated using ANNOVAR. Twenty-eight SNVs in the CYP3A4, CYP3A5, and ABCB1 genes were selected from all called SNVs based on the RefGene annotation (Supplementary Table 1). We manually checked the sequence alignment and the quality of selected SNVs using IGV 2.8.9 to exclude false-positive variant calls.

Statistical analysis
To evaluate the influence of C1.5/C0 ratio on post-transplant eGFR and the incidence of BPAR, t-tests and χ2 tests were used. A logistic regression analysis was performed to investigate the independent contributions of demographic and transplant-related variables to the likelihood of having BPAR. Variables from univariate analyses with P values of < 0.20 were considered for inclusion in the final multivariable model. Associations between the flat pattern peak group and SNV carriers were calculated using the logistic regression test for the following genetics models: additive, dominant, and recessive. To correct the effects of clinical variables, the impact of SNVs was further investigated by adjusting the clinical variables. Benjamini-Hochberg multiple testing correction was conducted to estimate the false discovery rate (FDR). FDR adjusted P value < 0.05 were considered statistically significant. All statistical analyses were performed using SPSS Statistics 26.0 software (SPSS Inc., Chicago, IL, USA) and R 3.6.3 software (The R Foundation for Statistical Computing, Vienna, Austria).

Ethics statement
This study was approved by the Institutional Review Board of Seoul National University Hospital (IRB no. 1608-037-784). The study was performed in accordance with the Declaration of Helsinki, and written informed consent was obtained from all participants.

RESULTS
Baseline characteristics
A total of 95 patients were enrolled in this study. Among them, 28 patients were included in the flat pattern peak group, and 67 patients were included in the control group. The mean C1.5/C0 value were 1.13 ± 0.22 and 3.78 ± 1.25 in the flat pattern peak and control groups, respectively (P = 0.002). The mean dose normalized trough concentration (C0/D) was
significantly higher in the flat pattern peak group than in the control group (2.9 ± 2.4 vs. 1.0 ± 0.6 ng/mL/mg; P < 0.001). The patients in the flat pattern peak group were older and had a higher rate of deceased donor transplantation (Table 1). Patients did not take other medications known to interact with tacrolimus.14,15

**Clinical outcomes**

BPAR was higher in the flat pattern peak group than in the control group (42.9% vs. 23.9%) within 3 years after transplantation, however it did not reach statistical significance (P = 0.080). The mean time interval between transplantation and BPAR diagnosis were 3.9 ± 5.0 (median 1, range 1 – 12) and 5.2 ± 5.4 (median 3, range 1 – 12) months in the flat pattern peak and control groups, respectively. The overall incidence of BPAR and/or borderline change was significantly higher in patients with a flat pattern peak (85.7% vs. 59.7%; P = 0.007). Ten (35.7%) patients in the flat pattern peak group and 13 (19.4%) patients in the control group showed suggestive calcineurin inhibitor toxicity in pathologic examination (P = 0.111). The mean eGFRs were significantly higher in the normal group at 1-week, 3-months, 12-months, and 36-months after transplantation (Table 2).

**Table 1. Baseline characteristics of study population**

| Variables                        | Flat pattern peak (n = 28) | Control group (n = 67) | P   |
|----------------------------------|---------------------------|------------------------|-----|
| Age, yr                          | 51.0 ± 12.4               | 42.7 ± 13.6            | 0.007|
| Female                           | 8 (28.6)                  | 26 (38.8)              | 0.482|
| Body weight, kg                  | 68.6 ± 13.9               | 58.6 ± 12.7            | 0.001|
| BMI, kg/m²                       | 24.3 ± 3.9                | 21.3 ± 3.25            | < 0.001|
| Hypertension                     | 23 (82.1)                 | 43 (65.2)              | 0.139|
| Diabetes mellitus                | 14 (50.0)                 | 10 (15.2)              | 0.001|
| Donor age                        | 49.3 ± 15.6               | 45.2 ± 11.8            | 0.157|
| Recipient-donor relation         |                           |                        | 0.068|
| Living-related                   | 7 (25.0)                  | 33 (49.3)              |      |
| Living-unrelated                 | 6 (21.4)                  | 13 (19.4)              |      |
| Deceased                         | 15 (53.6)                 | 21 (31.3)              |      |
| HLA mismatching, No.             | 3.3 ± 1.5                 | 2.7 ± 1.7              | 0.614|
| Graft weight, g                  | 174.9 ± 36.9              | 166.4 ± 29.8           | 0.286|
| Donor final creatinine, mg/dL    | 0.93 ± 0.33               | 0.93 ± 0.43            | 0.970|
| Tacrolimus C₀, ng/mL             | 8.2 ± 3.6                 | 8.0 ± 2.6              | 0.802|
| C₀/C₁,b                            | 1.13 ± 0.22               | 3.78 ± 1.25            | 0.002|
| C₀, ng/mL                        | 8.1 ± 3.6                 | 8.0 ± 2.6              | 0.828|
| C₀/daily dose, ng/mL/mg          | 2.9 ± 2.4                 | 1.0 ± 0.6              | < 0.001|
| C₁,b/daily dose, ng/mL/mg        | 3.1 ± 2.4                 | 3.5 ± 2.0              | 0.539|

Values are presented as mean ± SD or number (%). BMI = body mass index, HLA = human leukocyte antigen.

*C₀, tacrolimus concentration before a dose, trough level; *C₁,b, tacrolimus concentration at 1.5 hours after a dose.

**Table 2. Outcomes of transplantation**

| Variables                        | Flat pattern peak (n = 28) | Control group (n = 67) | P   |
|----------------------------------|---------------------------|------------------------|-----|
| Delayed graft function           | 3 (10.7)                  | 3 (4.5)                | 0.359|
| BPAR                             | 12 (42.9)                 | 16 (23.9)              | 0.080|
| Borderline change                | 14 (50.0)                 | 31 (46.3)              | 0.823|
| BPAR and/or borderline change    | 24 (85.7)                 | 40 (59.7)              | 0.007|
| Estimated GFR                    |                           |                        |     |
| Postoperative 1-wk               | 54.94 ± 28.79             | 70.36 ± 26.76          | 0.018|
| Postoperative 3-mon              | 51.98 ± 15.25             | 59.53 ± 15.17          | 0.033|
| Postoperative 1-yr               | 52.88 ± 15.16             | 62.73 ± 14.02          | 0.007|
| Postoperative 3-yr               | 51.41 ± 16.76             | 64.55 ± 15.55          | 0.001|

BPAR = biopsy proven acute rejection, GFR = glomerular filtration rate.
Factors associated with BPAR
To evaluate the association between the flat pattern peak of tacrolimus and BPAR and/or borderline change, a logistic regression analysis was performed. In multivariate analysis, flat pattern peaks remained an independent risk factor for BPAR and/or a borderline change (odds ratio [OR], 7.000; 95% confidence interval [CI], 1.489–32.897; \( P = 0.014 \)) (Table 3).

Factors associated with the 36-months eGFR
To investigate the association between the flat pattern peak of tacrolimus and post-transplant 36-month eGFR, univariate and multivariate linear regression analyses were performed. The flat pattern peak was associated with decreased post-transplant 36-month eGFR in univariate analysis. However, the association did not remain significant in multivariate analysis. Older donors and the higher body mass index of recipients showed significant associations with the post-transplant 36-month eGFR (Supplementary Table 2).

Variant association with flat pattern peak
Among 28 SNVs in the \( CYP3A4 \), \( CYP3A5 \), and \( ABCB1 \) genes, 2 were significantly associated with flat pattern peaks. In the \( ABCB1 \) gene, rs1922242, and rs2235035 were significantly associated with flat pattern peaks (adjusted \( P = 0.019 \) and 0.027, respectively). The effect of SNVs was investigated following adjustments for the clinical variables. Among the 11 variables included in the univariate analysis, recipient’s age, sex, body weight, donor type, and diabetes were included in multivariate analysis. In multivariate logistic regression model, the association between flat pattern peaks and SNVs in \( ABCB1 \) remained significant. The \( ABCB1 \) rs1922242 TT genotype was significantly more common in the flat pattern peak group (OR, 1.508; 95% CI, 1.184–1.922; adjusted \( P = 0.001 \)) (Table 4). In addition, the \( ABCB1 \) rs2235035 AA genotype was significantly more common in the flat pattern peak group (OR, 1.434; 95% CI, 1.132–1.817; adjusted \( P = 0.004 \)) (Table 5). Logistic regression with 2 SNVs and clinical variables was

### Table 3. Multivariate logistic regression analysis for predicting biopsy-proven acute rejection and/or borderline change

| Variables                              | Univariate |                       |                          | Multivariate |                       |                          |
|-----------------------------------------|------------|------------------------|--------------------------|--------------|------------------------|--------------------------|
|                                          | OR         | 95% CI                 | \( P \)                  | OR           | 95% CI                 | \( P \)                  |
| Sex, female                             | 0.742      | 0.301–1.827            | 0.516                    |              |                        |                          |
| Recipient age > 60 yr                   | 2.000      | 0.519–7.714            | 0.314                    |              |                        |                          |
| Hypertension                            | 1.667      | 0.639–4.344            | 0.296                    |              |                        |                          |
| Diabetes mellitus                       | 1.942      | 0.643–5.869            | 0.239                    |              |                        |                          |
| BMI > 25 kg/m²                          | 1.913      | 0.574–6.375            | 0.291                    |              |                        |                          |
| Deceased donor                          | 2.042      | 0.788–5.292            | 0.142                    | 1.394        | 0.398–4.882            | 0.604                    |
| Donor age > 60 yr                       | 1.605      | 0.407–6.331            | 0.499                    |              |                        |                          |
| Donor creatinine > 1.5 mg/dL            | 1.931      | 0.206–18.089           | 0.564                    |              |                        |                          |
| HLA mismatching > 4                     | 2.049      | 0.729–5.763            | 0.174                    | 1.722        | 0.555–5.343            | 0.346                    |
| \( C_0 \) > 8                           | 1.265      | 0.548–2.920            | 0.583                    |              |                        |                          |
| Flat pattern peak                       | 5.200      | 1.420–19.039           | 0.013                    | 7.000        | 1.489–32.897           | 0.014                    |

\( \text{OR} = \text{odds ratio, CI = confidence interval, BMI = body mass index, HLA = human leukocyte antigen.} \)

### Table 4. Multivariate logistic regression analysis of the association between \( ABCB1 \) rs1922242 and flat pattern peak

| Variables                              |           |                       |                          | Recessive model (adjusted \( P = 0.019 \)) |
|-----------------------------------------|-----------|------------------------|--------------------------|-------------------------------------------|
|                                          | OR        | 95% CI                 | \( P \)                  | \( \text{OR} \)                          | \( \text{95\% CI} \) | \( \text{P} \) |
| Genotype, TT                            | 1.508     | 1.184–1.922            | 0.001                    | \( \text{OR} \)                          | \( \text{95\% CI} \) | \( \text{P} \) |
| Recipient age, yr                       | 1.003     | 0.997–1.009            | 0.316                    | \( \text{OR} \)                          | \( \text{95\% CI} \) | \( \text{P} \) |
| Sex, female                             | 1.013     | 0.848–1.212            | 0.880                    | \( \text{OR} \)                          | \( \text{95\% CI} \) | \( \text{P} \) |
| Diabetes mellitus                       | 1.425     | 1.184–1.714            | \(< 0.001 \)             | \( \text{OR} \)                          | \( \text{95\% CI} \) | \( \text{P} \) |
| Recipient body weight, kg               | 1.010     | 1.004–1.016            | 0.002                    | \( \text{OR} \)                          | \( \text{95\% CI} \) | \( \text{P} \) |
| Deceased donor                          | 1.229     | 1.045–1.445            | 0.015                    | \( \text{OR} \)                          | \( \text{95\% CI} \) | \( \text{P} \) |

\( \text{OR} = \text{odds ratio, CI = confidence interval.} \)
conducted to investigate the interaction effects of 2 SNVs. Coefficient of interaction of 2 SNVs was statistically significant (OR, 2.698; 95% CI, 1.055–6.902; \( P = 0.041 \)) (Table 6).

**DISCUSSION**

This study is the first to report patients who showed a unique pattern of initial tacrolimus absorption. They did not exhibit a definite peak in the early absorption phase. In patients with flat pattern peaks, the time-concentration curve would be different from what we expect. If a dose of tacrolimus is administered based on the trough level, the total tacrolimus exposure would be lower than predicted, and which could increase the risk for acute rejection. Suboptimal immunosuppression can occur although the physicians carefully monitor the trough level and the patients have good medication adherence in flat pattern peak group.

Our data showed that patients with flat pattern peak had a higher risk of BPAR and/or borderline change within 3 years after transplantation. Acute rejection is well known risk factors for long term graft failure.\(^{16}\) Borderline change is also reported to be independently associated with poor long term graft outcomes.\(^{17,18}\) Thus, flat pattern peak causes the increased risk of BPAR and/or borderline change and can be associated with poor long term graft outcomes.

Limited sampling strategy (LSS) is an abbreviated regression analysis using several time points has been proposed to predict AUC.\(^{19,20}\) There is a controversy on the optimal collection time and frequency of blood sampling. Aouam et al.\(^{19}\) showed that 2-time point LSS using \( C_0 \) and \( C_{1.5} \) is reliable, accurate, and practical to estimate the AUC of tacrolimus regardless of the posttransplantation time. The TDM of tacrolimus has been extensively performed by determining \( C_{1.5} \).\(^{5}\) However, measurement of both \( C_{1.5} \) and \( C_0 \) is important.
to distinguish the patients with unique drug absorption patterns. After determining the group of patients with a flat pattern peak, both C₁₅ and C₀ were measured after kidney transplantation.

This study demonstrated the SNVs that were associated with this patient groups. Several extensive studies have been conducted to examine the pharmacogenomics of tacrolimus. Some genetic variants were associated with the pharmacokinetics of tacrolimus. However, genotyping to select the optimal dose is not recommended because of the lack of data regarding its effects on clinical outcomes.²¹,²² Although the current study was conducted using only a small sample of patients, it could be considered meaningful as it illustrated the different pharmacokinetics of tacrolimus and associated genetic variants, also with the effects on patients’ clinical outcomes.

CYP genes, especially CYP3A4 and CYP3A5, are important for the disposition of tacrolimus.²³ The most studied polymorphism is CYP3A5*3 (rs776746). Compared to CYP3A5*3/3 carriers, CYP3A5*1 carriers show increased metabolism of tacrolimus.²⁴ Tacrolimus is transported out of the cells via P-glycoprotein, which is encoded by the ABCB1 gene.²⁵ The highly variable intestinal expression of ABCB1 is an important determinant of the tacrolimus absorption.²⁶ The ABCB1 3435C>T (rs1045642), 1236C>T (rs1128503) and 2677G>T/A (rs2032582) SNVs have been extensively investigated; however, their functional significance remains unclear.²⁷ Our data showed 2 SNVs in ABCB1 gene, rs1922242, rs2235035, were associated flat pattern peaks. They were not previously reported to be associated with tacrolimus concentration. They could be used as candidate SNVs in further studies and validation using larger patient cohorts is required.

Our study focused on the CYP3A4, CYP3A5, and ABCB1 genes because their role in the pharmacogenomics of tacrolimus have been largely investigated and reported. The flat pattern absorption might be due to the interplay between metabolism and drug transporter. Vanhove et al.²⁸ showed that the effect of ABCB1 on the tacrolimus dose requirement was modulated by the CYP3A genotype. Highly active efflux pumps were required to maintain both a low intracellular concentration of tacrolimus and CYP3A capacity, when tacrolimus metabolism was slow.²⁸ When the drug transporter function was activated, the proportion of drug pumped out of the intestinal enterocytes increased, leading to higher clearance and lower blood concentrations of tacrolimus. Thus, the combined effect of CYP3A and ABCB1 polymorphisms in patients with flat pattern peaks is also worth investigating.

When a flat pattern peak is suspected, one of the generic form can be used. Generic tacrolimus is associated with a higher dose-normalized peak concentration and shorter time to peak concentration both during the early period and under steady-state conditions compared to the reference tacrolimus product.²⁹ Once-daily formula can be tried. Once-daily formula tacrolimus is absorbed in more distal intestine compared to the twice-daily formulas.³⁰,³⁴ ABCB1 expression increases from stomach and duodenum to colon.³² Our data showed that flat pattern peaks were associated with SNVs in ABCB1 gene. The different expression of ABCB1 gene in gastrointestinal tract might influence the absorption of once-daily and twice-daily tacrolimus differently in patients with flat peaks. After conversion, analysis of blood samples for evaluating the pharmacokinetic profiles is mandatory. In 6 patients with flat peaks, the C₁₅/C₀ ratio ranged from 2.0 to 3.3 after switching to a once-daily formula. Conversion to other immunosuppressant or increasing the dose of antimetabolites can be considered.
This study has a number of limitations. First, this is a retrospective study including small number of selected patients during the study period, which can cause lower statistical power. We did not include the consecutive patients during the study period, which might cause selection bias. Second, most of the patients underwent blood sampling to access the tacrolimus level within a year after transplantation, but not all of them did. The pharmacokinetics of tacrolimus are affected by bowel motility, which changed according to the period after transplantation. Third, it is possible that patients who had early graft loss due to the flat pattern peak of tacrolimus were not included in this study. We found the group of patients with flat peaks, recently. Thus patients had repeated BPAR and graft loss due to flat peak could not be identified. Finally, long term follow-up is needed to show the subsequent results, such as graft failure or antibody-mediate rejection. However, it is limited to follow up the study population longer without changing the immunosuppressant. Ethical problem should be considered for a study with long term follow up, because flat peak can be associated with poor clinical outcome.

In conclusion, a group of patients showed a unique pattern of tacrolimus absorption after kidney transplantation. Measurement of $C_{1.5}$ along with the trough level was performed to identify these patients. A $C_{1.5}/C_0$ ratio < 1.5 was associated with an increased risk of BPAR and/or borderline change. The SNVs, rs1922242 and rs2235035 in $ABCB1$ gene were associated with flat pattern peaks. Because this is a preliminary study with small number of patients, further study using a large cohort of patients is required to validate the importance of these candidate SNVs.

**SUPPLEMENTARY MATERIALS**

**Supplementary Table 1**
Twenty-eight single nucleotide variants (SNVs) in $CYP3A4$, $CYP3A5$, and $ABCB1$ selected from all called SNVs based on RefGene annotation

**Supplementary Table 2**
Univariate and multivariate linear regression analysis for factors affecting post-transplant 36-month estimated glomerular filtration rate

**REFERENCES**

1. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. *Clin Pharmacol Ther* 2015;98(1):19-24. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/26006392/) [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/26006392/)

2. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. *Clin J Am Soc Nephrol* 2007;2(2):374-84. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/17499688/) [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/17499688/)

3. Stift F, Stolk LM, Undre N, van Hooff JP, Christiaans MH. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. *Transplantation* 2014;97(7):775-80. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/24499342/) [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/24499342/)
4. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. *Nephrol Dial Transplant* 2003;18(Suppl 1):i12-5.

5. Mathew BS, Fleming DH, Jeysaeelean V, Chandy SJ, Annapandian VM, Subbanna PK, et al. A limited sampling strategy for tacrolimus in renal transplant patients. *Br J Clin Pharmacol* 2008;66(4):467-72.

6. Picard N, Bergan S, Marquet P, van Gelder T, Wallermaeq P, Hesselink DA, et al. Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs. *Ther Drug Monit* 2016;38 Suppl 1:S57-69.

7. Birdwell K. Role of pharmacogenomics in dialysis and transplantation. *Curr Opin Nephrol Hypertens* 2014;23(6):570-7.

8. Sohn M, Kim MG, Han N, Kim JW, Gim J, Min SI, et al. Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients. *Sci Rep* 2018;8(1):18064.

9. Roufosse C, Simmonds N, Claesen-van Groningen M, Haas M, Henriksen KJ, Horsfield C, et al. A 2018 reference guide to the Banff classification of renal allograft pathology. *Transplantation* 2018;102(11):1795-814.

10. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* 2011;43(5):491-8.

11. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010;38(16):e164.

12. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. *Nat Biotechnol* 2011;29(1):24-6.

13. Trofe-Clark J, Lemonovich TL; AST Infectious Diseases Community of Practice. Interactions between anti-infective agents and immunosuppressants in solid organ transplantation. *Am J Transplant* 2013;13 Suppl 4:318-26.

14. U.S. Food & Drug Administration. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Updated 2020. Accessed June 14, 2021.

15. Min SI, Park YS, Ahn S, Park T, Park DD, Kim SM, et al. Chronic allograft injury by subclinical borderline change: evidence from serial protocol biopsies in kidney transplantation. *J Korean Surg Soc* 2012;83(6):343-51.

16. Min SI, Park YS, Ahn S, Park T, Park DD, Kim SM, et al. Chronic allograft injury by subclinical borderline change: evidence from serial protocol biopsies in kidney transplantation. *Transplant Direct* 2021;7(2):e663.

17. Nakazawa R, Yoshiike M, Nozawa S, Aida K, Katsuoka Y, Fujimoto E, et al. Clinically useful limited sampling strategy to estimate area under the concentration-time curve of once-daily tacrolimus in adult Japanese kidney transplant recipients. *PLoS One* 2019;14(12):e0225878.

18. Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. *Ther Drug Monit* 2019;41(3):261-307.
22. Khan AR, Raza A, Firasat S, Abid A. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis. *Pharmacogenomics* 2020;20(4):553-62. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/)

23. Huang L, Wang J, Yang J, Zhang H, Ni Y, Zhu Z, et al. Impact of CYP3A4/S and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome. *Pharmacogenomics* 2019;20(15):1071-83. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/)

24. Genvigir FD, Campos-Salazar AB, Felipe CR, Tedesco-Silva H Jr, Medina-Pestana JO, Doi SQ, et al. CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy. *Pharmacogenomics* 2020;21(1):7-21. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/)

25. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. *Clin Pharmacokinet* 2010;49(3):141-75. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/)

26. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. *Clin Pharmacokinet* 2001;40(3):159-68. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/)

27. Hesselink DA, Bouamar R, Elens L, van Schaik RH, van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. *Clin Pharmacokinet* 2014;53(2):123-39. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/)

28. Vanhove T, Annaert P, Lambrechts D, Kuypers DR. Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype. *Pharmacogenomics J* 2017;17(6):556-62. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/)

29. Min SI, Ha J, Kim YS, Ahn SH, Park T, Park DD, et al. Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. *Nephrol Dial Transplant* 2013;28(12):3110-9. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/)

30. Tremblay S, Nigro V, Weinberg J, Woodle ES, Alloway RR. A steady-state head-to-head pharmacokinetic comparison of all FK-506 (Tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study. *Am J Transplant* 2017;17(2):432-42. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/)

31. Caillard S, Moulin B, Buron F, Mariat C, Audard V, Grimbert P, et al. Advagraf®, a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. *Transpl Int* 2016;29(8):860-9. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/)

32. Thörn M, Finnström N, Lundgren S, Rane A, Lööf L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. *Br J Clin Pharmacol* 2005;60(1):54-60. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://pubmed.ncbi.nlm.nih.gov/)